PMID- 26989965
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160323
LR  - 20160319
IS  - 0924-2708 (Print)
IS  - 0924-2708 (Linking)
VI  - 18
IP  - 3-4
DP  - 2006 Jun
TI  - Mirtazapine: only for depression?
PG  - 130-43
LID - 10.1111/j.1601-5215.2006.00143.x [doi]
AB  - BACKGROUND: Mirtazapine is an antidepressant first approved in the Netherlands in 
      1994 for the treatment of major depressive disorder. However, evidence suggests 
      its effectiveness in a variety of other psychiatric disorders and non-psychiatric 
      medical conditions. OBJECTIVE: The present paper reviews the published literature 
      on the off-label indications of Mirtazapine. METHODS: A search of the relevant 
      literature from MEDLINE, PsycLIT and EMBASE databases, included in the Science 
      Citation Index and available up to March 2006, was conducted using the terms 
      mirtazapine, case-reports, open-label trials and randomized controlled trials. 
      Only articles referring to conditions other than major depression were included 
      in this present review. RESULTS: Off-label use of mirtazapine has been reported 
      in panic disorder, post-traumatic stress disorder, generalized anxiety disorder, 
      social phobia, obsessive-compulsive disorder, dysthymia, menopausal depression, 
      poststroke depression, depression as a result of infection with human 
      immunodeficiency virus, elderly depression, Methylenedioxymethamphetamine 
      (MDMA)-induced depression, hot flashes, alcohol and other substance use 
      disorders, sleep disorders, sexual disorders, tension-type headaches, cancer 
      pain, fibromyalgia, schizophrenia and other less frequent conditions. 
      CONCLUSIONS: So far, data on the off-label usefulness of mirtazapine are limited 
      and mainly based on observations from case reports or open-label studies. 
      However, positive cues suggest that confirmation of these preliminary data with 
      randomized controlled trials may give sufficient evidence to warrant the use of 
      mirtazapine in a broad range of disorders.
FAU - San, Luis
AU  - San L
AD  - 1Department of Psychiatry, Hospital de San Rafael, Barcelona, Spain.
FAU - Arranz, Belen
AU  - Arranz B
AD  - 1Department of Psychiatry, Hospital de San Rafael, Barcelona, Spain.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Acta Neuropsychiatr
JT  - Acta neuropsychiatrica
JID - 9612501
EDAT- 2006/06/01 00:00
MHDA- 2006/06/01 00:01
CRDT- 2016/03/19 06:00
PHST- 2016/03/19 06:00 [entrez]
PHST- 2006/06/01 00:00 [pubmed]
PHST- 2006/06/01 00:01 [medline]
AID - S0924270800003458 [pii]
AID - 10.1111/j.1601-5215.2006.00143.x [doi]
PST - ppublish
SO  - Acta Neuropsychiatr. 2006 Jun;18(3-4):130-43. doi: 
      10.1111/j.1601-5215.2006.00143.x.